Pharmafile Logo
Pharmafocus logo
Advanced Search

Blueprint Medicines

Showing 3 posts of 3 posts found.

shutterstock_273326141

Roche and Blueprint extend collaboration with $1.7 billion cancer drug development and commercialisation deal

July 14, 2020
Manufacturing and Production, Research and Development Blueprint Medicines, Cancer, Roche, pralsetinib

Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib …

News

US approval for Blueprint Medicines’ gastrointestinal stromal tumour therapy

January 10, 2020
Medical Communications, Sales and Marketing Ayvakit, Blueprint Medicines, Cancer, pharma

The FDA has moved to authorise Blueprint Medicines’ kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal …

News

Blueprint Medicines agrees $1 billion-plus deal with Roche for cancer therapy

March 16, 2016
Business Services, Research and Development, Sales and Marketing Blueprint Medicines, Deals, Immunokinases, Roche, drug development

Blueprint Medicines Corp (Nasdaq: BPMC) said it has signed an over $1 billion deal with oncology drug giant Roche (SIX: ROG) …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024